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To identify potential biomarkers associated with Alzheimer’s disease (AD)-like neuropathologies in
the murine brain, we conducted proteomic analyses of neocortices from TgCRND8 mice. Here we
found that phosphoprotein enriched in astrocytes 15 kDa (PEA-15) is expressed at higher levels in
the neocortical proteomes from 6-month old TgCRND8 mice, as compared to non-transgenic mice.
Immunostaining for PEA-15 revealed reactive astrocytes associated with the neocortical amyloid
plaques in TgCRND8 mice and in post-mortem human AD brains. This is the ﬁrst report of increased
PEA-15 expression in reactive astrocytes of an AD mouse model and human AD brains.
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Alzheimer’s disease (AD), a neurodegenerative disease charac-
terized by the presence of amyloid deposits, neuroﬁbrillary tangles
and neuronal loss [1], is currently the leading cause of dementia,
estimated to affect approximately 35.6 million people worldwide
[2]. While no treatment exists for AD, studies have shown that ac-
tive medical management of individuals diagnosed with AD can
improve their quality of life [3], suggesting that early diagnosis
of AD would allow for a potentially better outcome for patients.
There remains, however, a lack of reliable and early diagnostic bio-
markers for AD, with deﬁnitive diagnosis still relying on postmor-
tem neuropathological ﬁndings of amyloid plaques and
neuroﬁbrillary tangles [4].The TgCRND8mouse model shows both amyloid deposition and
cognitive deﬁcits by 3 months of age, as well as amyloid deposition
patterns similar to that seen in human AD patients [5]. These mice
express a mutated form of the human amyloid precursor protein
(APP) under the control of the hamster prion promoter. This APP
contains 2 common mutations seen in individuals with familial
AD, the Swedish (K670N, M617L) and Indiana (V717F) mutations
[5]. These mutations near the b-secretase and c-secretase cleavage
sites on APP are believed to enhance its cleavage, and thus lead to
an accelerated generation and accumulation of the amyloid-b pep-
tide (Ab). The TgCRND8 mouse model is useful as an AD research
tool due to its robust and early onset Ab pathology [5]. The aim
of the present study was to conduct an unbiased broad-spectrum
proteomic analysis of the neocortices from TgCRND8 mice, with
the expectation of revealing potential biomarkers or therapeutic
targets for AD. We have identiﬁed and validated that PEA-15
(phosphorylated protein enriched in astrocytes, 15 kDa) is found
at higher levels in the neocortices of 6-month old TgCRND8 mice,
as compared to age-matched non-transgenic littermates. Impor-
tantly, we show that PEA-15-immunopositive reactive astrocytes
surround those plaques in the brains of TgCRND8 mice and those
amyloid plaques in the postmortem brains of AD patients.
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2.1. Animals and tissue collection
TgCRND8 mice and non-transgenic littermates (both males and
females) were maintained on a C3H/C57Bl6 background [5] with
food and water ad libitum. All methods were approved by the Uni-
versity of Toronto’s Animal Care Committee, following the guide-
lines set forth by the Canadian Council on Animal Care. Under
deep anesthesia with sodium pentobarbital, these animals were
perfused transcardially with either (1) 0.1 M phosphate buffered
saline (PBS; pH 7.4, 50 ml volume) to allow for harvest of fresh
tissues for proteomic analyses; (2) 4% paraformaldehyde in 0.1 M
PBS (pH 7.4) to obtain ﬁxed tissues for immunolocalization at the
light microscope level; and (3) 2% paraformaldehyde and 2% glu-
taraldehyde in 0.1 M PBS (pH 7.4) to obtain ﬁxed tissues for exam-
ination at the transmission electron microscope level. The fresh or
ﬁxed neocortices were removed from each animal. The fresh tis-
sues were placed in labeled tubes and snap frozen in liquid nitro-
gen, and the ﬁxed tissues were stored in ﬁxative. For fresh tissue
collection, 6-month old transgenic and non-transgenic mice
(n = 10 mice per genotype) were sacriﬁced, and for ﬁxed tissue col-
lection, both 3- and 6-month old transgenic and non-transgenic
mice (n = 14 per age and genotype) were sacriﬁced for ﬁxation.2.2. Isoelectric focusing and 2 dimensional (2D) gel electrophoresis
Individual samples of frozen neocortices were homogenized in
whole tissue homogenization buffer containing 8 M urea, 2 M thio-
urea, 4% w/v CHAPS in 15 mM Tris (pH 7.0). Samples were centri-
fuged and supernatants were stored at 80 C. Protein
concentration was determined using the 2D-Quantiﬁcation Kit
(Amersham Biosciences, Baie d’Urfe, QC, Canada). 200 lg of sample
protein was reduced using 1% (w/v) DTT for 15 min and diluted to
450 ll in rehydration buffer containing 8 M urea, 2 M thiourea, 4%
(w/v) CHAPS, 2% (v/v) HED and 0.5% ampholytes. 24-cm (pH range
4–7) immobilized pH gradient (IPG) strip gels (Amersham) were
rehydrated overnight at room temperature in the buffer containing
the sample protein.
Isoelectric focusing was carried out on a Protein IEF cell ma-
chine (BioRad; Mississauga, ON, Canada, Queen’s University Pro-
tein Function Discovery Facility) according to the following
program: 8 h at 250 V; 1 h at 500 V; 1 h at 1000 V; 3 h linear ramp-
ing to 10000 V; 65 kV h at 10000 V. Focused IPG strips were stored
at 80 C to prevent protein diffusion. A minimum of four IPG (pI
4–7) strips were prepared for each sample (three pools of cortices
per phenotype).
2D SDS–PAGE was carried out according to Graham and col-
leagues [6]. Focused IPG strips were treated for 20 min in equili-
bration buffer containing 8 M urea, 30% (v/v) glycerol and 2% SDS
in 50 mM Bis–Tris (pH 8.8), supplemented with 1% (w/v) DTT
and again for 20 min in equilibration buffer supplemented with
2.5% (w/v) iodoacetamide. Equilibrated strips were placed on top
of 1 mm thick 10% acrylamide gels (with Bis–Tris (pH 7.4)) and
large format 2D SDS–PAGE electrophoresis was carried out in a
DALT6 apparatus (Amersham) in 1 MOPS electrophoresis buffer
and run at 80 V at 4 C overnight. Gels were stained with a stan-
dard silver stain [7] and scanned using a UMAX Powerlook2100XL.
Gels were dried between porous cellophane sheets for spot exci-
sion and long-term storage.
2.3. Spot identiﬁcation and mass spectrometry
Protein samples were prepared for mass spectroscopy according
to McDonald and colleagues [8]. Scanned images of gels were ana-lyzed manually, and overlaid images were compared visually to
identify differences in location or intensity of corresponding spots
(relative to background and surrounding spots). Spots were se-
lected as candidates for further processing if the difference in
abundance was present in every gel from transgenic compared to
non-transgenic proteome (i.e., three pools of cortices per pheno-
type, four gels per phenotype, and four spots picked from every
phenotype). Candidate spots were then manually excised from
the gels, rehydrated and de-stained with aqueous 15 mM potas-
sium ferricyanide and 50 mM sodium thiosulfate. Gel plugs di-
gested with 6 ng/ml trypsin (sequencing Grade-modiﬁed trypsin;
Promega, Napean, ON, Canada) for 5 h at 37 C. Peptides were ex-
tracted using 1% formic acid/2% acetonitrile followed by 50% aceto-
nitrile. Extraction solutions were combined and evaporated down
to 10 ll. Peptides were spotted onto a MALDI target plate on top
of a re-crystallized spot of alpha-cyanno-4-hydroxy-cinnamic acid
matrix and spectra were collected using a Voyager DE-Pro matrix-
assisted laser desorption ionization time of ﬂight massspectrome-
ter (MALDI-TOF MS; PerSeptive Biosystems, Framingham, MA,
USA). Peaks were analyzed using Data Explorer software; spectra
were adjusted to baseline, noise ﬁltered, externally calibrated
against a spectrum of a known 4-peptide mix and internally cali-
brated against Trypsin I and Trypsin III peaks, when present. Search
parameters allowed for one missed cleavage as well as peptide oxi-
dation and carbamidomethylation. Peptide masses were manually
selected and the resulting peak mass lists were searched against
the NCBI database using the peptide mass ﬁngerprinting database
search tool MASCOT PMF search engine (http://www.matrix-
science.com). Spectra which did not contain adequate peaks to
get a statistically signiﬁcant hit (signiﬁcance as determined by
MASCOT) were ZIP-TIPPED (Millipore Corporation, Bedford MA,
USA) and eluted into 70% acetonitrile in 0.1% TFA in ddH2O to pur-
ify and concentrate the peptides and new MS spectra were col-
lected. Only protein identiﬁcations with statistically signiﬁcant
MOWSE scores and which approximately matched the predicted
molecular weight and pI values were included.
2.4. Immunoblotting
For 2D immunoblotting, 200 lg of protein per sample was di-
luted to 450 ll in rehydration buffer and run out on 24-cm IPG
strips (pH 4–7; Amersham) and equilibrated as described above.
Equilibrated strips were placed on top of 1 mm thick 10% acrylam-
ide gels (with Bis–Tris (pH 7.4)) and large format 2D SDS–PAGE
electrophoresis was carried out as also described above. A 7.0 cm
section of the 10% acylamide gel which contained the spot identi-
ﬁed as phosphoprotein enriched in astrocytes 15 kDa (PEA-15) was
cut out and transferred (for 1 h at 0.4 Å) onto nitrocellulose mem-
branes. Membranes were blocked and then incubated in primary
antibody against rabbit anti-PEA-15 IgG (dilution 1:500; Abcam,
Cambridge, MA) at room temperature for 2 h. After rinsing, the
membranes were incubated in goat anti-rabbit IgG (1:10,000;
HRP conjugated; Jackson Immunoresearch, West Grove, PA, USA).
Membranes were then treated with Chemi-Illuminescence (Amer-
sham) according to the manufacturer’s protocol.
2.5. Electron microscopy
Neocortical mouse tissues ﬁxed with 2% paraformadehyde and
2% gluataraldehyde were cut at 100 lm thickness using a Vibra-
tome. The sections were trimmed into 1  1 cm2 pieces, which
were subsequently ﬁxed overnight in 1% phosphate-buffered os-
mium tetroxide. After rinsing and dehydrating through a graded
series of methanols, the sections were cleared with propylene
oxide and embedded Epon. Both semithin and ultrathin sections
were cut using a LKB Ultramicrotome, the latter of which were col-
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citrate. Stained ultrathin sections were viewed and photographed
with a Hitachi 7000 transmission electron microscope.
2.6. Post-mortem human neocortical tissues
Human specimens were obtained from a collection of classiﬁed
parafﬁn-embedded frontal and temporal neocortical tissues. Non-
AD tissues included those from the following three adults: (1)
72-year old female who died of coronary artery disease; (2) 76-
year old male who died of coronary artery disease; and (3) 88-year
old male who died of pneumonia. None of these tissues had AD-
associated changes. AD tissues included those from the following
four adults: (1) 71-year old male with an AD Braak score of 6/6;
(2) 73-year old male with an AD Braak score of 4/6; (3) 78-year
old female with an AD Braak score 5/6; and, 88-year old female
with an AD Braak score of 5/6.
2.7. Immunohistochemistry
Fixed mouse brains were sectioned at 40 lm thickness using a
freezing microtome. The sections were collected in 0.1 M Tris buf-
fered saline (TBS; pH 7.4) and processed for the immunohisto-
chemical detection of PEA-15, as well as glial ﬁbrillary acidic
protein (GFAP; astrocyte marker; DakoCytomation), Ionized cal-
cium binding adaptor molecule 1 (Iba1, microglial marker), and
neuronal nuclei (NeuN; neuronal marker; Millipore). Sections
were ﬁrst incubated in 0.3% hydrogen peroxide in 0.1 M TBS for
1 h and then 10% bovine serum albumin (BSA) in 0.1 M Tris and
0.25% TritonX-100 (TBX) for 1 h at room temperature. Sections
were then incubated in avidin and biotin for 1 h each at room
temperature. Next, sections were incubated in rabbit anti-GFAP
IgG (1:1000), rabbit anti-Iba1 IgG (1:1000), or mouse anti-NeuN
IgG (1:1000) (each diluted in 3% BSA in TBX) for two days at room
temperature. After rinsing in 0.1 M TBS for 15–30 min, the sec-
tions were incubated with biotinylated goat anti-rabbit IgG
(1:100; Vector Laboratories) for 2 h at room temperature. The
sections were then incubated with avidin–biotin complex (Elite
ABC Peroxidase kit; Vector Laboratories) for 2 h at room temper-
ature. The sections were then reacted in a solution containing
0.05% diaminobenzidine (DAB) tetrahydrochloride, 0.04% nickel
chloride, and 0.015% hydrogen peroxide in 0.1 M TBS until the
brown reaction product was clearly visible, as viewed with a ste-
reomicroscope. The sections were then immediately transferred
into buffer to stop the reaction. The sections were rinsed thor-
oughly (3) in 0.1 M TBS for no less than 30 min. For the benzi-
dine dihydrochloride (BDHC) blue reaction, sections were ﬁrst
rinsed in 0.01 M phosphate buffer (pH 6.6) for 30 min, and then
incubated in 10% BSA in 0.25% TBX for 1 h at room temperature.
Next the sections were incubated in rabbit anti-PEA-15 IgG
(1:500) or GFAP (1:1000) diluted in 3% BSA in 0.25% TBX for
2 days at room temperature. After rinsing in 0.1 M TBS, the sec-
tions were incubated with biotinylated goat anti-rabbit IgG
(1:100; Vector Laboratories) for 2 h at room temperature. The
sections were then incubated with avidin–biotin complex (Elite
ABC Peroxidase kit; Vector Laboratories) for 2 h at room temper-
ature. The sections were then reacted in a solution containing
0.01% BDHC, 0.025% sodium nitroferricyanide, and 0.03% hydro-
gen peroxide in 0.01 M phosphate buffer (pH 6.6). Once the blue
crystalline reaction product was clearly visible, the reaction was
stopped by rinsing the sections in 0.01 M PBS (pH 6.6). Sections
were then mounted onto slides, dried overnight at room temper-
ature, dehydrated through a graded series of ethanols, cleared in
HistoClear, and then coverslipped in Permount mounting media.
Sections were viewed under bright ﬁeld optics, and images were
acquired using a Zeiss microscope and Axiovision software.Procedures for immunostaining of human neocortical tissues
were the same as that described above, with the only exception
being that the parafﬁn-embedded tissues (already mounted on
slides) were cleared of parafﬁn and hydrated to water before incu-
bating in 0.3% hydrogen peroxide.3. Results
Neocortical proteins were fractionated by 2D gel electrophore-
sis. No fewer than three individual samples of neocortices iso-
lated from 6-month old TgCRND8 and non-transgenic
littermates were resolved and silver-stained to reveal protein spot
differences. Four proteins were found to be consistently present
at more abundant levels in the TgCRND8 proteomes, as compared
to age-matched non-transgenic proteomes (Fig. 1). Using mass
spectrometry, two of these proteins in the TgCRND8 proteomes,
labeled 3 and 4 (Fig. 1A, B) were identiﬁed as PEA-15 and Ab,
respectively. The spot for PEA-15 on the silver-stained gels was
consistently more intense in the TgCRND8 proteomes, as com-
pared to the non-transgenic proteomes. The spot for Ab on the sil-
ver-stained gels was consistently found only in the TgCRND8
proteomes, providing direct evidence of the ectopic expression
of Ab in these transgenic mice. To validate the presence of PEA-
15 in the neocortical proteomes of 6-month old TgCRND8 (as
compared to the neocortical proteomes of non-transgenic mice),
protein samples were again fractioned by 2D gel electrophoresis
(with no subsequent silver staining) and then transferred to
membranes for immunoblotting. Membranes were incubated
with PEA-15 those having TgCRND8 neocortical tissues yielded
two immunopositive spots, where as the non-transgenic neocorti-
cal tissues did not (insets of Fig. 1A and B). These spots had
molecular weights of 15 kDa and isoelectric points of pH 5,
and were consistent with previously reported 2D gelmigration
patterns for PEA-15 [9]. Since PEA-15 can exist in non-phosphor-
ylated, single-phosphorylated, or double-phosphorylated forms
[9], the identiﬁcation of two immunopositive spots may represent
shifts in the phosphorylation status of PEA-15 in the brains of 6-
month old TgCRND8 mice.
Regarding the described phenotype of 3- and 6-month old
TgCRND8 mice, the single most conspicuous difference is the in-
creased incidence of Ab plaques throughout the neocortex of the
older aged mice. Non-transgenic littermates at both ages lacked
such Ab plaques (Fig. 1C; double immunostaining for NeuN (pan
neuronal marker) using the chromogen DAB to reveal positive
immunoreactivity – brown reaction product, and for PEA-15 using
the chromogen BDHC to reveal positive immunoreactivity – blue
reaction product). In 6-month old TgCRND8 mice, these plaques
found in the grey matter (Fig. 1D) and white matter (Fig. 1E) of
the neocortices displayed prominent immunostaining for PEA-15
(blue reaction product). The intensity of this plaque-associated
immunostaining was greater in the 6-month old TgCRND8 mice
as compared to their 3-month old transgenic counterparts (data
not shown). This immunostaining was deemed to be positive be-
cause no staining was seen in either the absence of the primary
anti-PEA-15 IgG or the presence of the incorrect secondary IgG
(e.g., using biotinylated rabbit-anti-goat IgG). Positive immuno-
staining for PEA-15 (blue reaction product) was also seen among
capillaries of both transgenic and non-transgenic mice, likely con-
ﬁned to the end-foot processes of astrocytes. Double immunostain-
ing for GFAP (brown reaction product) and PEA-15 (blue reaction
product) yielded GFAP-immunopositive reactive astrocytes associ-
ated with plaques in the neocortices of 6-month old TgCRND8
mice; importantly, these GFAP-immunopositive astrocytes dis-
played positive immunoreactivity for PEA-15 (Fig. 1F). Double
immunostaining for Iba1 (using the chromogen DAB) and GFAP
Fig. 1. Silver-stained 2D gels of neocortical proteins from 6 month old non-transgenic mice (A) and age-matched TgCRND8 mice (B) revealed 4 protein differences between
these two proteomes. Mass spectrometry identiﬁed these proteins as small nuclear RNA-activating complex polypeptide 1 (spot 1), IgG-dependent histamine-releasing factor
(spot 2), phosphoprotein enriched in astrocytes (PEA-15, spot 3), and amyloid-b (spot 4). Immunostaining for PEA-15 on 2D gels of neocortical tissues from 6 month old non-
transgenic and TgCRND8 mice (insets in A and B) revealed two protein spots only in the proteomes of transgenic mice. Neocortical tissues of 6 month old non-transgenic mice
(C) displayed PEA-15-immunopositive blood vessels among NeuN-immunopositive neurons. Neocortical tissues of 6 month old TgCRND8 mice (D, E) displayed PEA-15-
immunopositive blood vessels among NeuN-immunopositive neurons, as well as PEA-15-immunopositive plaques (D, box; E, circle) in both the grey and deep white matter.
These neocortical plaques (⁄ in F) were surrounded by reactive astrocytes displaying positive immunostaining for GFAP (brown reaction product) and PEA-15 (blue reaction
product). These neocortical plaques (⁄ in G) were composed of Iba1-immunopositive microglia (brown reaction product) and were surrounded by GFAP-immunopositive
reactive astrocytes (blue reaction product). Scale bars = 100 lm (C, D) and 20 lm (F, G).
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tive microglial cells in the core of the neocortical plaques of 6-
month old TgCRND8 mice; in contrast to the reactive astrocytes,
these Iba1-immunopositive microglial cells displayed no positive
immunoreactivity for GFAP; double immunostaining with Iba1
and PEA-15 failed to label PEA-15-positive astrocytes in the neo-
cortices of 6-month old TgCRND8 mice (Fig. 1G).The presence of PEA-15 immunostaining in those reactive astro-
cytes associated with neocortical plaques of 6-month old TgCRND8
mice warranted further examination of these glial cells at the
ultrastructural level. Reactive astrocytes in immediate proximity
to dystrophic neurites in the plaques had fragmented rough endo-
plasmic reticulum, pieces of which were found in smaller astro-
cytic processes throughout the plaques (Fig. 2A and B).
Fig. 2. Transmission electron microscopy of neocortical plaques from 6 month old TgCRND8 mice revealed astrocytic processes (shaded blue) having fragmented pieces of
rough endoplasmic reticulum (arrowheads) (A, B); these astrocytic processes were in close proximity to dystrophic neurites (⁄). Neocortical tissues (frontal lobe) from an AD
patient having a Braak score of 4/6 had plaques surrounded by reactive astrocytes immunopositive for both GFAP (brown reactive product) and PEA-15 (blue reaction
product) (C, D). Some of these reactive astrocytes were also seen extending processes to adjacent blood vessels (BV). Though control neocortical tissues (frontal lobe) from a
non-AD patient lacked plaques, astrocytes in grey and white matter displayed positive immunostaining for GFAP (brown reactive product) and PEA-15 (blue reaction product)
(E, F). Scale bars = 1 lm (A), 0.8 lm (B), 20 lm (C, D), and 40 lm (E, F).
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reactive astrocytes associated with neocortical (frontal and tempo-
ral) plaques in specimens diagnosed with AD (Braak scores ranging
from 4/6 to 6/6). These plaque-associated reactive astrocytes dis-
played positive immunostaining for PEA-15 (Fig. 2C and D). These
same PEA-15-immunopositive reactive astrocytes could be seen
extending processes in and around the plaques, as well as toward
adjacent capillaries. It is important to note that PEA-15 immunore-
activity was found through the neocortices of both AD and non-AD
human specimens, including both neuropil and adjacent whitematter tracts (Fig. 2C–F). This pattern was not seen in either trans-
genic or non-transgenic mice, in which PEA-15 immunoreactivity
was restricted to those reactive astrocytes associated with the pla-
ques of TgCRND8 mice.
4. Discussion
PEA-15 is a death effector domain (DED) containing protein
found predominantly in the central nervous system, with expres-
sion previously observed in astrocytes and neurons alike [10]. This
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between the mouse and human forms [11]. PEA-15 was originally
described as a protein related to diabetes mellitus and is now
known to be involved in regulating numerous other cell processes
[9]. The N-terminal DED in PEA-15 has led to investigations into its
role in regulating apoptosis [9,10,12]. More recently it has been
discovered that PEA-15 has a diverse set of regulatory functions,
including roles in proliferation, glucose metabolism, cell cycle con-
trol, cell adhesion, migration and autophagy and its expression has
been shown to be altered in various cancers [9,10,12–14].
Given the diversity of functions attributed to PEA-15, its en-
hanced detection among plaque-associated reactive astrocytes in
TgCRND8 mice might have beneﬁcial effects, exacerbate glial
pathology, and/or merely serve as a by-product of the disease state.
Though the scope of our study did not include a functional analysis
of increased PEA-15 expression in the neocortices of TgCRND8
mice, it is tempting to speculate that PEA-15 expression in pla-
que-associated reactive astrocytes may be playing an anti-apopto-
tic role in this glial sub-population. It has been previously shown
that PEA-15 expression decreases the susceptibility of astrocytes
to tumor necrosis factor alpha (TNFa)-induced apoptosis, provid-
ing a possible mechanism as to why astrocytes are often resistant
to apoptosis during inﬂammation or disease states [10]. Neuroin-
ﬂammation plays a large role in the pathogenesis of AD [15] and
increased TNFa levels have been found in patients with AD
[16,17]. Further, in the TgCRND8 mouse model, intense TNFa
immunostaining has been observed in reactive microglia and
astrocytes surrounding Ab plaques in the neocortex and hippocam-
pus [18]. Therefore, it is possible that increased PEA-15 expression
in plaque-associated reactive astrocytes may protect the astrocytes
from apoptosis induced by TNF in the vicinity of the Ab plaques. It
is also possible that a more general relationship may exist between
astrocyte PEA-15 expression and the diseased central nervous sys-
tem, given that ‘‘marked‘‘ PEA-15 expression was found in reactive
astrocytes located in the grey matter of the spinal cord of an ALS
mouse model (SOD1 G93A mutant) [12].
As previously mentioned, our report provides direct and vali-
dated evidence that detection of PEA-15 is increased in the brains
of an AD mouse model. Contrary to our study, Takano et al. [19] re-
ported a decrease in PEA-15 expression in the hippocampus of
APPE693D mice (as determined solely by quantitative comparison
between wild type and transgenic hippocampal proteomes). This
discrepancy may be explained by certain differences between the
two studies, including the different mouse models and brain re-
gions examined. Our experiments used the TgCRND8 model of
AD, which shows the presence of Ab oligomers, ﬁbrils and plaques
[5,20], whereas the Takano et al. [19] assessed the APPE693Dmodel,
which generates Ab oligomers in the absence of plaques [19]. Given
that we localized increased PEA-15 immunodetection exclusively
to plaque-associated reactive astrocytes, we propose that the gen-
eration of Ab-containing plaques is critical to PEA-15 expression in
surrounding astrocytes. In the absence of Ab-containing plaques, as
seen in the APPE693D mouse model, a similar localization of PEA-15
to reactive astrocytes is unlikely to occur. Further, the altered PEA-
15 expression observed in the two studies was found in two differ-
ent brain regions: Takano and colleagues reported decreased
expression of PEA-15 in the hippocampus of APPE693D mice [19],
whereas we detected increased PEA-15 expression in the neocor-
tices of TgCRND8 mice. Finally, our proteomic discovery of in-
creased levels of PEA-15 in the neocortices of TgCRND8 mice was
validated by immunostaining of brain tissues and immunoblotting
of brain proteins in these mice. Most importantly, we provide
translational evidence that increased PEA-15 immunostaining of
plaque-associated reactive astrocytes in transgenic mice is also
seen in human AD tissue, where Ab plaques are surrounded by
PEA-15-immunopositive reactive astrocytes.Collectively, these data show that 2D gel electrophoresisfrac-
tionation of neocortices from 6-month old TgCRND8 and non-
transgenic mice yields consistent patterns of differential expres-
sion for several proteins, in particular increased levels of Ab and
PEA-15. Using mass spectrometry, Ab was only found in the prote-
omes of TgCRND8 mice, conﬁrming its accumulation in the brains
of these transgenic animals. The other protein of interest, PEA-15,
was detected at high levels in the proteomes of TgCRND8 mice;
this increase in PEA-15 was conﬁrmed by both immunoblotting
and tissue immunostaining. In the neocortices of the TgCRND8
mice, PEA-15 expression was localized to plaque-associated reac-
tive astrocytes, a pattern that was also observed in post-mortem
human AD tissue. As a biomarker of AD, increased levels of astro-
cytic PEA-15 may be used, along with other pathological hallmarks,
to assess severity of the disease progress at the time of death. Fu-
ture studies will assess whether PEA-15 is detectable in human
cerebrospinal ﬂuid and/or serum, and if such detection can be
linked to cognitive impairment associated with AD prior to death.
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